Truist raised the firm's price target on Quest Diagnostics to $225 from $220 and keeps a Hold rating on the shares after its Q1 earnings beat. Core trends were strong with organic volumes nicely ahead aided by FMS/Corewell and core tests remaining a nice tailwind, the analyst tells investors in a research note.
